Our overall findings thus suggest that the three different Eiken syndrome mutations can have different effects on the receptor, including both gain and loss of function effects, depending on the cell type expressing the receptor and the intended endogenous ligand, PTH or PTHrP. The gene discussed is PTH; the disease is Eiken syndrome.